How to buy Gilead Sciences shares | US$74.71

Own your own GILD stock in just a few minutes.

Posted

Fact checked

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.

US$74.71
current price
US$-0.9
change
-1.19%
change %

How to buy stock in Gilead Sciences

  1. Compare share trading platforms. To buy shares in a US company from New Zealand you’ll need to find a trading platform that offers access to US stock markets. If you’re just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, including your ID. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Gilead Sciences. Find the share by name or ticker symbol: GILD. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Gilead Sciences reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At today's price of US$74.71, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Gilead Sciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Gilead Sciences. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
  7. Price details for Gilead Sciences (GILD)

    Open $75.11 Previous close $75.61
    High $75.84 Change $-0.9
    Low $73.95 Change % -1.19%
    Close $74.71 Timestamp 1594324800
    Volume N/A GMT offset 0

    Gilead Sciences stock price

    Use our graph to track the performance of GILD stocks over time.

    Compare share trading platforms

    Data indicated here is updated regularly
    Name Product Monthly fee Currency conversion fee Available markets
    Stake
    $0
    1% ($2 min)
    NASDAQ
    NYSE
    BATS
    Chicago Stock Exchange
    And more
    Sign up through Finder and use referral code "FINDERNZ" for a free stock. Trade 3,500 US listed stocks and ETFs through Stake with $0 brokerage.
    loading

    Compare up to 4 providers

    The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

    Gilead Sciences company summary

    Information last updated 2020-06-27.

    Gilead Sciences (GILD) is a leading Biotechnology business based in the USA. Gilead Sciences (GILD) is listed on the NASDAQ and employs 11800 staff.

    Profile

    Industry Drug Manufacturers—General Currency symbol $
    Code GILD Country name USA
    Type Common Stock Country ISO US
    Name Gilead Sciences, Inc ISIN US3755581036
    Exchange NASDAQ CUSIP 375558103
    Currency code USD Sector Healthcare
    Currency name US Dollar Full-time employees 11800

    Detailed company information

    Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.

    Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
Go to site